Distinguished in Alveolar Soft Part Sarcoma

Dr. Sosipatros A. Boikos

Hematology Oncology | Hematology | Oncology
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Distinguished in Alveolar Soft Part Sarcoma
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sosipatros Boikos is a Hematologist Oncology specialist and a Hematologist in Richmond, Virginia. Dr. Boikos is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Synovial Sarcoma, Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Neuroendocrine Tumor, and Bone Marrow Aspiration. Dr. Boikos is currently accepting new patients.

His clinical research consists of co-authoring 47 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in VA
Languages Spoken
English
Greek
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

1250 E Marshall St, Internal Medicine, Richmond, VA 23298

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Biological
Study Phase: Phase 1
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Other, Drug, Procedure
Study Drugs: Cediranib Maleate, Olaparib
Study Phase: Phase 2
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 24, 2025
Intervention Type: Procedure, Drug
Study Drugs: Olaparib, Temozolomide
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drugs: Letetresgene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
A Phase 1/2 Study of Venetoclax and Irinotecan in Relapsed/Refractory Small Cell Lung Cancer
A Phase 1/2 Study of Venetoclax and Irinotecan in Relapsed/Refractory Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: March 03, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

47 Total Publications

Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma.
Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma.
Journal: JCO precision oncology
Published: July 02, 2025
Similar Doctors
Advanced in Alveolar Soft Part Sarcoma
Dr. Radhika M. Thorn
Hematology Oncology | Hematology | Oncology
Advanced in Alveolar Soft Part Sarcoma
Dr. Radhika M. Thorn
Hematology Oncology | Hematology | Oncology

Bon Secours-Richmond Community Hospital LLC

14051 St Francis Blvd, Suite 2210, 
Midlothian, VA 
 (13.6 miles away)
804-893-8717
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Radhika Thorn is a Hematologist Oncology specialist and a Hematologist in Midlothian, Virginia. Dr. Thorn is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. Her top areas of expertise are Hemochromatosis, Small Cell Lung Cancer (SCLC), Familial Colorectal Cancer, and Pleuropulmonary Blastoma. Dr. Thorn is currently accepting new patients.

Advanced in Alveolar Soft Part Sarcoma
Dr. Andrew Poklepovic
Hematology | Oncology
Advanced in Alveolar Soft Part Sarcoma
Dr. Andrew Poklepovic
Hematology | Oncology

Mcv Associated Physicians

1001 E Leigh St, 
Richmond, VA 
 (1.9 miles away)
804-828-7929
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Poklepovic is a Hematologist and an Oncologist in Richmond, Virginia. Dr. Poklepovic is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Melanoma, Angiosarcoma, Merkel Cell Carcinoma, Adult Soft Tissue Sarcoma, and Bone Marrow Aspiration.

Experienced in Alveolar Soft Part Sarcoma
Dr. John F. Miller
Hematology Oncology | Hematology | Oncology
Experienced in Alveolar Soft Part Sarcoma
Dr. John F. Miller
Hematology Oncology | Hematology | Oncology

Peninsula Cancer Institute, LLC

120 Kings Way, Suite 3100, 
Williamsburg, VA 
 (42.6 miles away)
757-345-5724
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Miller is a Hematologist Oncology specialist and a Hematologist in Williamsburg, Virginia. Dr. Miller is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Paget Disease of the Breast, Large-Cell Immunoblastic Lymphoma, and Chronic Lymphocytic Leukemia (CLL). Dr. Miller is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Boikos's expertise for a condition
ConditionClose
    View All 18 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 104 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile